What it sells
Simple tests for complex diseases.
Business model breakdown
Buyer: who owns the budget?
UnverifiedLab directors or pathology and oncology departments.
Trigger: what makes them buy now?
Gene-expression signature tests normally need central reference labs, sequencing or microarrays with long turnaround and high cost.
Workflow: what inputs become what output?
Run a single multiplexed qPCR assay kit (PCRchitectur) on existing qPCR instruments to get a molecular signature result instead of sending samples to a central lab.
Economics: what it saves and how it charges
UnverifiedPlanned diagnostic kit sales (per-test consumables) running on customers' existing qPCR hardware.
Distribution: how it reaches customers
Not yet commercial; cart page states technology in development and not for sale.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2022 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.